Schizophrenia Clinical Trials in New York

Showing 81-100 of 184 trials

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

NCT00825539

Part 1 of the study will assess the enhancement of task-related brain activation (BOLD response) in key brain areas in schizophrenia during the performance of working memory, episodic memory and visual activation tasks as measured by functional magnetic resonance imaging (fMRI) in people with schizophrenia. Part 2 of the study will assess the safety and tolerability of multiple doses of AQW051 in people with schizophrenia.

Schizophrenia

Novartis Pharmaceuticals68 participantsStarted Jan 2009

Los Angeles, California, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +4 more locations

COMPLETEDPhase 4< 1 mile

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

NCT01981759

This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions. In addition to testing efficacy, this trial will characterize DCS effects in terms of time course and persistence of response and will examine DCS effects on memory consolidation and cognitive flexibility as possible mediators of DCS enhancement of CBT for delusions.

SchizophreniaSchizoaffective DisorderDelusional Disorder

NYU Langone Health58 participantsStarted Feb 2014

Baltimore, Maryland, United States • New York, New York, United States

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

Schizophrenia Trials in Other Cities

Can Cognitive Training Decrease Reactive Aggression?

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

Pediatric Open-Label Extension Study

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Long-term Study of Cariprazine in Patients With Schizophrenia

Safety and Efficacy of Cariprazine in Schizophrenia

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

Randomized Controlled Trial (RCT) of a Motivational Decision Support System

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Clozapine for Cannabis Use in Schizophrenia

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

Other Conditions in New York